A Robust and Promising Pipeline

MedImmune's historical roots are in infectious disease. In 1998 we were the first company to launch a monoclonal antibody in the United States targeting an infectious disease. This product, Synagis^® (palivizumab), today produces more than $1 billion in revenues worldwide and has been given to more than 1 million babies.

The company is also developing a vaccine to help prevent RSV, the most common cause of hospitalizations in children under one year of age, and is investigating whether antibodies can be used to treat infants hospitalized with this virus.

In 2008, MedImmune filed with the U.S. Food and Drug Administration for approval of an improved anti-RSV antibody, motavizumab.

MedImmune is driving innovation in influenza prevention, having introduced in 2003 the first influenza vaccine to use cutting-edge attenuated live virus technology (FluMist^® [Influenza Vaccine Live, Intranasal]). In 2007, we improved the formulation of FluMist^®, which significantly improved the storage and handling requirements for the vaccine. We also successfully expanded the label of the vaccine to include children as young as two years of age. We continually strive to seek ways to improve our flu vaccine and we're also exploring its role in helping prevent a worldwide influenza pandemic.

Beyond RSV and influenza, we are also exploring ways of bringing biologic technology to the most challenging infectious disease needs of our society. Research is ongoing in such diverse areas as herpes viruses, hepatitis C virus, antibacterials, and other respiratory viruses.

MedImmune is pursuing the discovery and development of valuable biologic therapies in areas of high unmet medical need for the treatment of respiratory, inflammatory and autoimmune diseases. In the United States alone, more than 50 million people are affected by these diseases, which typically impact life expectancy and patient's quality of life.

We are committed to finding innovative solutions that may one day help patients struggling with respiratory diseases. Currently in development are therapeutic approaches across a multitude of disease pathways that could potentially address diseases such as asthma and chronic obstructive pulmonary disease.

MedImmune is pioneering multistage research, evaluating the origins and effects of autoimmune and inflammatory disease, exploring novel disease pathways involved in rheumatic disease, and developing monoclonal antibodies as potential treatments for diseases such as systemic lupus erythematosus, rheumatoid arthritis, and scleroderma.

In oncology, we recognize that a significant therapeutic gap remains between desired efficacy and toxicity, which if closed, could extend lives and improve patient's quality of life. Biologics may offer both of these benefits to cancer patients due to specific targeting of cancer cells.

MedImmune's oncology product pipeline includes potential treatments for both liquid (lymphoma and leukemia) and solid (breast, lung, prostate, etc) tumors, which are being studied for use in both late- and early-stage disease.

At MedImmune, a wide range of opportunities in cardiovascular and gastrointestinal diseases are under investigation for improved treatment through biological approaches.

Our cardiovascular pipeline focuses on diseases including thrombosis and homeostasis, diabetes, and atherosclerotic disease. Treatments aimed at acute intervention in high-risk patients, as well as chronic treatment and long-term disease modification, have been identified as having potential for meeting unmet medical needs through specifically targeted biologics.

Multiple biological approaches to chronic pain refractory to current treatments are under investigation to address this significant problem.

In addition, MedImmune is actively investigating the opportunity to use biological approaches to address one of the most significant health issues of the future, Alzheimer's disease. Current treatments address symptoms only, and there is need for a therapy that addresses the underlying pathology of the disease, slowing the onset and progression of dementia.